非诺贝特制剂的研究进展  

Research progress of fenofibrate preparation

作　　者：冯巧巧 张天佑 刘荣 宋凯 明奕 胡敬峰 FENG Qiaoqiao;ZHANG Tianyou;LIU Rong;SONG Kai;MING Yi;HU Jingfeng(Shandong Center for Food and Drug Evaluation&Inspection,Jinan 250014,China)

机构地区：[1]山东省食品药品审评查验中心,山东济南250014

出　　处：《药学研究》2023年第3期199-203,共5页Journal of Pharmaceutical Research

摘　　要：非诺贝特属于贝特类降血脂药,是降低甘油三酯的首选药物之一,临床使用率高。由于非诺贝特难溶于水,不易于被吸收,导致生物利用度较低,影响药物疗效。为解决这一问题,不同类型的药物传递系统被应用与研究。本文综述非诺贝特制剂的研究进展,以期为其制剂的进一步开发提供思路。Fenofibrate belongs to the fibrate class of hypolipidemic drugs,and is one of the first-choice drugs for lowering triglycerides,with a high clinical usage rate.Since fenofibrate is insoluble in water and difficult to be absorbed,it leads to low bioavailability and reduced efficacy of the drug.To solve this problem,different types of formulations have emerged.This article reviewd the research progress of fenofibrate formulations,in order to provide ideas for the further development of its formulations.

关 键 词：非诺贝特 生物利用度 微粉化 包合技术 微粒分散系 

分 类 号：R972[医药卫生—药品]